树突状细胞 ( DC)疫苗策略已可用于临床 ,尤其可作为癌症治疗 ,因为已开发了DC负载抗原的方法 ,并可用这些负载细胞诱导抗肿瘤活性。但是 DC疫苗制备过程费时费力 ,分离自患者的 DC需先增殖培育至成熟 ,然后再负载抗原并回输给患者以诱导抗疾病免疫应答。因此从商业和医学观点 Dendritic cell (DC) vaccine strategies have been used clinically, especially as cancer therapies, as DC-loaded antigens have been developed and these loaded cells can be used to induce anti-tumor activity. However, the DC vaccine preparation process is time-consuming and labor-intensive. DCs isolated from patients need to be multiplied and grown to maturity prior to being loaded with the antigen and returned to the patient to induce anti-disease immune responses. So from a business and medical point of view